A Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP0010 in Asthmatic Children and Adolescents Over 6 Weeks
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2014
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors MAP Pharmaceuticals
- 28 Feb 2007 Interim results have been reported.
- 28 Feb 2007 Status change from initiated to completed.
- 04 Aug 2006 New trial record.